{"id":635340,"date":"2023-01-24T19:38:01","date_gmt":"2023-01-24T19:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=635340"},"modified":"2023-01-24T19:38:01","modified_gmt":"2023-01-24T19:38:01","slug":"phenylketonuria-market-is-projected-to-grow-significantly-during-the-forecast-period-20192032-key-companies-synlogic-synb1934-jnana-jnt517-homology-medicines-hmi102-biomarin-bmn-307","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/phenylketonuria-market-is-projected-to-grow-significantly-during-the-forecast-period-20192032-key-companies-synlogic-synb1934-jnana-jnt517-homology-medicines-hmi102-biomarin-bmn-307_635340.html","title":{"rendered":"Phenylketonuria Market is Projected to Grow Significantly During the Forecast Period (2019-2032) | Key Companies- Synlogic (SYNB1934), Jnana (JNT-517), Homology Medicines (HMI-102), BioMarin (BMN 307)"},"content":{"rendered":"
\n
\"Phenylketonuria<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Phenylketonuria Market is anticipated to grow in the coming years owing to the rise in the cases of Phenylketonuria, growth in the research and development activities by the pharma and biotech giants for the development of novel drugs, and the expected launch of emerging therapies in the market.<\/div>\n

Globally, several major pharma and biotech giants such as PTC Therapeutics, BioMarin Pharmaceuticals, Homology Medicines, and Synlogic are investigating their candidates for Phenylketonuria, and the emerging therapies are anticipated to hit the market in the near future.<\/p>\n

DelveInsight’s “Phenylketonuria Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Phenylketonuria market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Phenylketonuria market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Phenylketonuria<\/p>\n

Phenylketonuria: An Overview<\/strong><\/p>\n

Phenylketonuria (PKU) is an inborn metabolism error detected during the first days of life via routine newborn screening. PKU is characterized by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), responsible for processing the amino acid phenylalanine. Amino acids are the chemical building blocks of proteins and are essential for proper growth and development. With normal PAH activity, phenylalanine is converted to another amino acid, tyrosine. However, when PAH is absent or deficient, phenylalanine accumulates and is toxic to the brain.<\/p>\n

Without treatment, most people with PKU would develop a severe intellectual disability. To prevent intellectual disability, treatment consists of a carefully controlled, phenylalanine-restricted diet beginning during the first days or weeks of life.<\/p>\n

Phenylketonuria Market Key Facts<\/strong><\/p>\n